CICADABIO CO. LTD requests that their press release NewsItemId: 20260605635242 issued June 5, 2026 “CicadaBio Announces Oral Presentation on CC-18, a First-in-Class GLP-1/ActRII Fusion Protein Designed for Muscle-Preservation Weight Loss, at ADA 2026” be killed.
CC-18 is designed to address a growing challenge in obesity treatment: achieving meaningful weight loss while preserving muscle mass and improving long-term metabolic health.
Contacts
Investors:
Yan Zhang, MS, MBA
Head of Business Development
CicadaBio
707-623-7337
yan.zhang@cicadabio.com
Media:
Lauren Arnold
LA Communications
Lauren@LACommunications.net
If you believe this article contains misleading, harmful, or spam content, please let us know.
Report this article